MARKET

BIIB

BIIB

Biogen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

227.72
+1.66
+0.73%
After Hours: 226.76 -0.96 -0.42% 17:01 10/16 EDT
OPEN
226.23
PREV CLOSE
226.06
HIGH
229.75
LOW
225.96
VOLUME
1.38M
TURNOVER
--
52 WEEK HIGH
344.00
52 WEEK LOW
215.78
MARKET CAP
42.00B
P/E (TTM)
8.43
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BIIB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 30 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BIIB News

  • BofA Merrill Lynch sees 25% upside in Vertex in after-hours analyst action
  • Seeking Alpha - Article.8h ago
  • Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
  • Zacks.16h ago
  • Pelosi drug bill would save $345B - CBO
  • Seeking Alpha - Article.1d ago
  • Why Did the Market Whack This IPO?
  • MotleyFool.com.2d ago

More

Industry

Pharmaceuticals
+0.04%
Pharmaceuticals & Medical Research
0.00%

Hot Stocks

Name
Price
%Change

About BIIB

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
More

Webull offers Biogen Inc (BIIB) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.